Cancer Research Donn Young Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kundu, N.
Right arrow Articles by Fulton, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kundu, N.
Right arrow Articles by Fulton, A. M.
[Cancer Research 62, 2343-2346, April 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Selective Cyclooxygenase (COX)-1 or COX-2 Inhibitors Control Metastatic Disease in a Murine Model of Breast Cancer1

Namita Kundu and Amy M. Fulton2

Department of Pathology [N. K., A. M. F.] and Greenebaum Cancer Center [A. M. F.], University of Maryland School of Medicine, Baltimore, Maryland 21201

Using a highly metastatic mammary tumor cell line that expresses both cyclooxygenase (COX) isoforms, we now show that oral administration of either a selective COX-2 inhibitor (celecoxib) or a selective COX-1 inhibitor (SC560) to mice with established tumors results in significant inhibition of tumor growth. Administration of the dual inhibitor, indomethacin, leads to even better growth control. Metastatic capacity is also reduced by treatment of tumor-bearing mice with either COX-1 or COX-2 selective inhibitors. Pretreatment of tumor cells with COX inhibitors also reduces metastatic success, indicating that tumor cells may be a direct target of action by COX inhibitors. Growth of a second cell line, which does not express COX-2 in vivo, is also reduced by celecoxib, implicating both COX-dependent and COX-independent mechanisms.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. Wang, W. H. Shen, Y. J. Jin, P. W. Brandt-Rauf, and Y. Yin
A Molecular Link between E2F-1 and the MAPK Cascade
J. Biol. Chem., June 22, 2007; 282(25): 18521 - 18531.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Cancer Res., May 1, 2007; 67(9): 4507 - 4513.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
L. S. Fournier, V. Novikov, V. Lucidi, Y. Fu, T. Miller, E. Floyd, D. M. Shames, and R. C. Brasch
MR Monitoring of Cyclooxygenase-2 Inhibition of Angiogenesis in a Human Breast Cancer Model in Rats
Radiology, April 1, 2007; 243(1): 105 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Fulton, X. Ma, and N. Kundu
Targeting Prostaglandin E EP Receptors to Inhibit Metastasis.
Cancer Res., October 15, 2006; 66(20): 9794 - 9797.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al.
Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. M. Roth, M. Caunt, A. Cretu, A. Akalu, D. Policarpio, X. Li, P. Gagne, S. Formenti, and P. C. Brooks
Inhibition of Experimental Metastasis by Targeting the HUIV26 Cryptic Epitope in Collagen
Am. J. Pathol., May 1, 2006; 168(5): 1576 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Ma, N. Kundu, S. Rifat, T. Walser, and A. M. Fulton
Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis.
Cancer Res., March 15, 2006; 66(6): 2923 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Cui, C.-H. Yu, and K.-Q. Hu
In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells
Clin. Cancer Res., November 15, 2005; 11(22): 8213 - 8221.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. S. Diaz-Cruz, C. L. Shapiro, and R. W. Brueggemeier
Cyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer Cells
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2563 - 2570.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. G. Bottone Jr., Y. Moon, J. S. Kim, B. Alston-Mills, M. Ishibashi, and T. E. Eling
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3)
Mol. Cancer Ther., May 1, 2005; 4(5): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown and R. N. DuBois
COX-2: A Molecular Target for Colorectal Cancer Prevention
J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. De Larco, B. R. K. Wuertz, and L. T. Furcht
The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8
Clin. Cancer Res., August 1, 2004; 10(15): 4895 - 4900.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Lanza-Jacoby, A. P. Dicker, S. Miller, F. E. Rosato, J. T. Flynn, S. N. Lavorgna, and R. Burd
Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice
Mol. Cancer Ther., April 1, 2004; 3(4): 417 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Wei, L. Wang, Y. He, H. Q. Xiong, J. L. Abbruzzese, and K. Xie
Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity
Cancer Res., March 15, 2004; 64(6): 2030 - 2038.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. G. Bottone Jr, J. M. Martinez, B. Alston-Mills, and T. E. Eling
Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells
Carcinogenesis, March 1, 2004; 25(3): 349 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Lanza-Jacoby, S. Miller, J. Flynn, K. Gallatig, C. Daskalakis, J. L. Masferrer, B. S. Zweifel, H. Sembhi, and I. H. Russo
The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1486 - 1491.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda
Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy
Cancer Res., November 15, 2003; 63(22): 7845 - 7852.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Stover and M. Kester
Liposomal Delivery Enhances Short-Chain Ceramide-Induced Apoptosis of Breast Cancer Cells
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 468 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. V.V. Pardhasaradhi, A. M. Ali, A. L. Kumari, P. Reddanna, and A. Khar
Phycocyanin-mediated apoptosis in AK-5 tumor cells involves down-regulation of Bcl-2 and generation of ROS
Mol. Cancer Ther., November 1, 2003; 2(11): 1165 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
S. L. Beam, K. M. Rassnick, A. S. Moore, and S. P. McDonough
An Immunohistochemical Study of Cyclooxygenase-2 Expression in Various Feline Neoplasms
Vet. Pathol., September 1, 2003; 40(5): 496 - 500.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
D. O. McCarthy
Rethinking Nutritional Support for Persons with Cancer Cachexia
Biol Res Nurs, July 1, 2003; 5(1): 3 - 17.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice
Carcinogenesis, May 1, 2003; 24(5): 945 - 952.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.